The U.S. Food and Drug Administration (FDA) today announced the Approval of Moderna’s SpikeVax COVID-19 vaccine for adults 18 years and older.
SpikeVax has received Approvals from regulators in more than 70 countries, including Canada, Japan, Israel, the European Union, the UK.
Spikevax has the same formulation as the Authorized Moderna COVID-19 Vaccine and is administered as a primary series of two doses, one month apart.
SpikeVax Vaccine Approved by the U.S. FDA
COVID-19 Vaccinations, What Should We Do?
Vaccines are the essential weapon for preventing infections and fighting the COVID-19 pandemic. However, it is now well established that vaccines lose effectiveness over time, wrote Marcello Candelli, Emergency Department, Fondazione Universitaria Policlinico A Gemelli–IRCCS, Catholic University of Sacred Heart of Rome, in a recent editorial.
Arthropods Are Responsible for Transmitting Viruses, Bacteria, and Parasites
According to the World Health Organization (WHO), vector-borne diseases account for more than 17% of all infectious diseases, leading to more than 700,000 deaths annually.
And mosquitoes, ticks, and fleas are among the arthropods responsible for transmitting many of the bacteria, viruses, and parasites that cause most vectorborne diseases.
The February 2022’s Emerging Infectious Disease Volume 28, Number 2 cover picture features a collage of images arrayed like mug shots for a number of these creatures responsible for many vector-borne diseases across the globe.
‘Stealth’ Version of Omicron Variant No Cause for Alarm, Experts Say
New version of the variant does not appear to cause more severe disease, and vaccines are effective against it
FDA Gives Moderna COVID-19 Vaccine Full Approval
Vaccine, which has been available for the age group under emergency use authorization, will be marketed as Spikevax
Three mRNA Vaccine Doses Protective Against Delta, Omicron
However, odds ratios were higher for omicron suggesting that booster doses are less protective than against delta
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Jan. 24 to 28, 2022. This …
Remdesivir May Benefit Adults Early in COVID-19 Course
Real-world data support the use of remdesivir for hospitalized COVID-19 patients receiving no oxygen or low-flow oxygen
Thrombosis, Thrombocytopenia Syndrome Up After Ad26.COV2.S
Reporting rates 3.83 per million vaccine doses for Ad26.COV2.S versus 0.00855 per million for mRNA-based vaccines
ALA Report Cites Progress Made in Reducing Tobacco Use
E-cigarette use reported by more than 2 million middle and high school students in 2021; considerable disparities reported in smoking